Founded 70 years ago, the new China remaining on the track of fast growth is embracing a flourishing future;

 

Hansoh Pharma incorporated 24 years ago has been maintaining a strong momentum through constant innovation.

 

The company has never changed its commitment to pharmaceutical R&D;

 

Building on its momentum, the company is embarking on a high-quality development journey.

 

Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (“Hansoh Pharma”) was incorporated in July 1995 in Lianyungang, Jiangsu, when China’s market economy paradigm took shape and was optimized. Thanks to its forward-looking R&D strategy and constant innovations over the past decades, the company had launched the Class-I anti-infectives Mailingda (Morinidazole and Sodium Chloride Injection) and Fulaimei (Polyethylene Glycol Loxenatide Injection) – China’s first patented long acting diabetes drug, and will introduce the Flumatinib Mesylate Tablets for chronic myeloid leukemia (CML), and the third-generation targeted drug Xinwei (Imatinib Mesylate Tablets) for non-small cell lung cancer (NSCLC) patients soon. Major breakthroughs in a series of innovative new drugs justify Hansoh Pharma’s accelerating transition from the follow-on to the innovation-led imitation approach and epitomize China’s magnificent transformation from a big to a powerful pharmaceutical producer. Over the past two decades, the company has been playing an instrumental role in driving transition of China’s pharmaceutical industry by adhering to the approach of change-driven innovation and innovation-driven development and by proactively integrating itself into and aligning itself with the national strategy.

 

R&D investment strategy aligned with the national agenda

China as the second largest pharmaceutical consumer in the world is less powerful in drug innovation, lack of IPR-protected innovative drugs. At the National Health Convention, president Xi Jinping reiterated “prosperity for all is impossible without health for all”. As the “13th Five-year Plan” was unveiled, “Healthy China” had become a national strategy, opening up a historical opportunity for development of the pharmaceutical industry. It has been an industrial consensus that technical innovation will accelerate the industrial transformation and empower “Healthy China”.

 

In technical sense, it is safe to depict the long-turnaround, high-cost and big-difficulty nature of medicine R&D with the phrase “10 years + RMB1 billion + 10%”. At the onset, Hansoh Pharma had embarked on a tough journey of innovation-led development, committed to enhancing its core competence on the strength of leading technical expertise.

 

The company has always been maintaining high-intensity R&D investment, which has exceeded 12% of its total sales revenue now, much higher than the industrial average at 1-2%.

 

It has formed a complete R&D system encompassing a national-level center of competence, a post-doctoral workstation, and a regional engineering center.

 

Focusing its R&D efforts in the areas of central nervous system, tumors and diabetes, Hansoh Pharma has been partnering with renowned research institutes and hospitals in and outside of China to promote efficient technology-to-market transformation.

 

Saving no effort to bring up and introduce high-profile technical talents, the company now hires more than 1,200 full-time R&D workers, providing a reliable talent reserve for the National Hundred-Thousand-Ten Thousand Talent Program, Jiangsu Provincial Innovation and Entrepreneurship Program and the Talent Program 333.

 

Improve medicine accessibility to contribute to “Healthy China” 

Demands for medicines of Chinese people have changed from “having medicines to use” to “having access to new and good drugs”. Hansoh Pharma takes the responsibility to meet Chinese people’s demands for health and improve security of the national healthcare strategy.

 

Focusing on medicines badly needed in clinical practices, Hansoh Pharma has eliminated the patent barrier to significantly reduce the medication cost and improve drug accessibility and affordability, while ensuring efficacy and safety of its products. The psychotropic drug Olanzapine Tablets announced in 2001, which features good efficacy, low side effects and cost, has been a comfort to the local patients. Xinwei®（Imatinib Mesylate Tablets）, a generic drug that was introduced in 2013 as the patent of Imatinib Mesylate Tablets compound expired in China, is a safe, efficient and cost-effective alternative well received by local patients. Since 2000 the company has launched more than 20 generic drugs, benefiting tens of millions patients and saving tens of billions healthcare cost.

 

While generic drugs help address the challenge of medicine accessibility；innovative drugs deliver more profound impacts to the society at large. The new third-generation nitroimidazoles Mailingda provides better efficacy and safety for treatment of pelvic infection and similar gynaecopathia diseases. R&D of the innovative Fulaimei well reflects the company’s commitment to its corporate responsibility as a native pharmaceutical manufacturer. As the population of diabetes patients increased significantly in China, high expectation was imposed upon R&D of new drugs. Hansoh Pharma rose up to this stunning challenge in 2004, less than 10 years after inception. In 15 years, from new drug discovery, clinical research to assessment and approval, the company’s technical team addressed the three major technical challenges of modification, preparation and quality control of the long acting drug, and realized an innovative dosage of once a week, bringing an efficient, safe and convenient choice to the patients and more clinical benefits, and significantly improving the diabetes patients’ medication experience and life quality.

 

Focusing on independent innovation to expand from local to international markets

Hansoh Pharma will take more social responsibilities by focusing on innovation to deliver more indigenous drugs to satisfy the increasing health demands of China as a populous nation.

Addressing the major clinical requirements, especially in the areas of central nervous system, tumor, anti-infection, diabetes, digestive tract and cardiovascular medication, Hansoh Pharma has been remaining on track to innovate new drugs delivering high quality and efficacy for more than 20 years. It ever completed more than 40 technical breakthrough projects under the Program 863, the National Major Drug Innovation and the Program Torch, winning two national sci-tech advance awards (second prize), one China Patent Gold Award and holding more than 200 invention patents granted in and outside of China. The company also contributed to nearly 150 national standards.

 

To gain a bridgehead in the global competition, Hansoh Pharma had paved the way to bring more innovative drugs including Imatinib Mesylate Tablets to multi-center FESTnd study, laying a solid foundation to move up from “go-out”. In its go-global journey, the company, aiming at the technical frontier, is committed to setting the trend of drug R&D by investing heavily in development of efficient medication, to bring leading-edge drugs to patients in China and around the world.

 

Celebrating the 70th anniversary of the new China, the 24-year-old Hansoh Pharma will open up a new chapter to accelerate technical innovation, and lead the industrial transformation and upgrade to satisfy the medication requirements of the patients and contribute to the “Healthy China 2030” initiative. It is also well positioned to tap potentials in the broader international market under the banner “Serve the society and create health”!